Reduction in Liver Cancer Risk by Quercetin via Modulation of Urate Levels: Insights from Drug-Target Mendelian Randomization
Genes · 2025
DOI: 10.3390/genes16040449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Zhengwen Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Chengdu University, 2025 Chengluo Avenue, Chengdu 610106, China. Hauptthemen laut MEDLINE: Quercetin, ATP Binding Cassette Transporter, Subfamily G, Member 2, Liver Neoplasms, Uric Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Talent Introduction Project of Chengdu University (X2107, Y2021066)., National Natural Science Foundation of China, Talent Introduction Project of Chengdu University.
Abstract (Originalsprache)
Background
Quercetin, a dietary flavonoid and a widely used supplement, has hepatoprotective properties. Given its urate-lowering effects and epidemiological evidence linking elevated serum urate levels to liver cancer risk, we tested whether quercetin reduces liver cancer risk via modulation of urate levels by bioinformatics methods.
Methods
We employed drug-target Mendelian randomization using genome-wide association study summary statistics from public databases (e.g., MRC-IEU) to assess genetic associations, and integrated these findings with GEO datasets (such as GSE138709 and GSE179443) and immune infiltration analyses using tools like xCell, TIMER.
Results
Our analyses identified ABCG2-mediated urate elevation as a causal risk factor for hepatocellular carcinoma (OR = 1.001, p < 0.01), cholangiocarcinoma (OR = 3.424, p < 0.01), and liver fibrosis (OR = 2.528, p < 0.01). Single-cell transcriptomics revealed elevated ABCG2 expression in cholangiocarcinoma endothelial cells, while immune infiltration analysis showed significant associations between ABCG2 expression and both endothelial cell and macrophage infiltration. Survival analysis further indicated that ABCG2 was not associated with poor prognosis in cholangiocarcinoma or hepatocellular carcinoma.
Conclusions
Considering quercetin’s multifaceted interactions with BCRP/ABCG2, our findings support its potential use as a preventive dietary supplement for hepatic diseases rather than as an adjunctive therapy for established liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Chengdu University, 2025 Chengluo Avenue, Chengdu 610106, China.
- Cell Biology-Inspired Tissue Engineering, Institute for Technology-Inspired, Regenerative Medicine, Maastricht University, 6200 MD Maastricht, The Netherlands.
- Precision Medicine, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6200 MD Maastricht, The Netherlands.
- College of Food Science and Engineering, Hainan University, 58 Renmin Road, Haikou 570228, China.
ORCID-Profile: Chujie Li
Förderung
- Talent Introduction Project of Chengdu University (X2107, Y2021066).
- National Natural Science Foundation of China
- Talent Introduction Project of Chengdu University
Zitieren
APA
Li, Z., Wang, Y., Yang, K., Li, C., & Zhang, M. (2025). Reduction in Liver Cancer Risk by Quercetin via Modulation of Urate Levels: Insights from Drug-Target Mendelian Randomization. Genes. https://doi.org/10.3390/genes16040449
Vancouver
Li Z, Wang Y, Yang K, Li C, Zhang M. Reduction in Liver Cancer Risk by Quercetin via Modulation of Urate Levels: Insights from Drug-Target Mendelian Randomization. Genes. 2025. doi:10.3390/genes16040449
BibTeX
@article{Li2025,
author = {Li, Zhengwen and Wang, Yue and Yang, Kaichuan and Li, Chujie and Zhang, Ming},
title = {Reduction in Liver Cancer Risk by Quercetin via Modulation of Urate Levels: Insights from Drug-Target Mendelian Randomization},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16040449}
}
EUVIMED